Figure 1 (Cinryze 01)
Cinryze Kit
Product Images NDC 42227-083
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 31 technical images submitted to the FDA as part of the official labeling for Cinryze (NDC 42227-083). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Cinryze 02)
Figure 3 (Cinryze 03)
Figure 4 (Cinryze 04)
Figure 5 (Cinryze 05)
Figure 6 (Cinryze 06)
Figure 7 (Cinryze 07)
Figure 8 (Cinryze 08)
Figure 9 (Cinryze 09)
Figure 10 (Cinryze 10)
Figure 11 (Cinryze 11)
Figure 12 (Cinryze 12)
Figure 13 (Cinryze 13)
Figure 14 (Cinryze 14)
Figure 15 (Cinryze 15)
Figure 16 (Cinryze 16)
Figure 17 (Cinryze 17)
Figure 18 (Cinryze 18)
Figure 19 (Cinryze 19)
Figure 20 (Cinryze 20)
Figure 21 (Cinryze 21)
Figure 22 (Cinryze 22)
Figure 23 (Cinryze 23)
Figure 24 (Cinryze 24)
Figure 25 (Cinryze 25)
Figure 26 (Cinryze 26)
Figure 27 (Cinryze 27)
Principal Display Panel (500 U Vial Label)
CINRYZE is a sterile water-based solution intended for intravenous injection, used for treating Hereditary Angioedema (HAE) attacks. The solution contains C1 esterase inhibitor which is human in origin. The medication needs to be reconstituted with sterile water and should be used within 3 hours of reconstitution. It is important to discard any unused contents. This is a single-dose medication and should only be used under prescription by a healthcare professional. The manufacturer of CINRYZE is YiroPhama Biologis LLC, located in Lexington, MA. The lot number is not available.*
Principal Display Panel (500 U Vial Carton)
This is a description of CINRYZE®, a medication used for intravenous injection. It is a C1 esterase inhibitor derived from human plasma and comes in a single-dose vial containing 500 U of the medication, which should be stored at 2°C=25°C (36°F77°F). Reconstitution requires 5 mL of Sterile Water for Injection, USP. The medication does not contain any preservatives and must be used within 3 hours of reconstitution. Inactive ingredients are listed in the package insert. The description warns that plasma-derived products, such as this medication, may carry a risk of transmitting infectious agents. Users should refer to the package insert for all warnings and precautions. The medication is manufactured by ViroPharma Bioogics LLC in Levington, MA, and is a product of Austria. The US License No. for this medication is 1833.*
Principal Display Panel (5 mL Vial Label)
This is a description of a single-dose container of sterile water used to reconstitute another product. The water should not be used if an antimicrobial agent or other substance has been added, and should not be injected intravascularly without making it isotonic by adding a suitable solute. The container should be discarded if any unused portion remains. It is only for prescription use and is nonpyrogenic.*
Principal Display Panel (Kit Carton)
This is a product description for CINRYZE, a C1 esterase inhibitor (human) used for intravenous injection. The product is manufactured in Austria and Germany, and contains a single 500 1U vial of CINRYZE and a 5 mL vial of sterile water for injection. The package insert should be consulted for full instructions and warnings.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
